AB2 Bio is developing drugs that will not only treat the symptoms but also target the underlying causes of inflammation-based …

April 3, 2017 - AB2 Bio Ltd’s Tadekinig alfa therapy receives Breakthrough Therapy Designation from the US Food and Drug …

AB2 Bio is pioneering an empirical therapeutic approach to a rational selection of medical targets. If patients with high levels of free …

AB2 Bio Ltd., located at the Innovation Park of the École Polytechnique Fédérale de Lausanne (EPFL), is a drug discovery and …

Contact Us AB2 Bio Ltd. EPFL Innovation Park Building B, 4th Floor CH-1015 Lausanne, Switzerland T +41 21 694 00 40 F +41 21 …

Proprietary Assay AB2 Bio has developed the first and only proprietary assay detecting free IL-18 allowing the identification of clinical …

"AB2 Bio has established a leading position in the development of therapies targeting IL-18-driven diseases," said Dr. Toru Nakai, …

AB2 Bio is a multicultural company. We hold the diversity of our staff in high regard and we are respectful of equality between …

De plus, AB2 Bio a développé le premier test propriétaire détectant l’IL-18 libre et permettant l'identification de maladies provoquées …

AB2 Bio SA Pipeline Clinical Development